Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement   EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones Amended agreement envisages [ … ]

 Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares Proceeds of up to EUR 15.0* million  Milan, Italy, March 14, 2024, 17:45 CET – Newron Pharmaceuticals S.p.A. (“Newron”, or the “Company”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients  [ … ]

Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS) Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and Level of Functioning (LOF) More than 70% of patients experienced clinically im [ … ]